FivePrime is dis­cov­er­ing and devel­op­ing nov­el ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cal­ly screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a giv­en clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cal­ly rel­e­vant pro­teins in med­ical­ly-focused assays at the high­est qual­i­ty stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tion­al “one pro­tein at a time”. The Pro­Screen Engine com­pris­es the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dent­ed in its effi­cien­cy, qual­i­ty and scale. In addi­tion to DBL Part­ners, investors include Domain Asso­ciates, Ver­sant Ven­tures, Klein­er Perkins Cau­field and Byers, Texas Pacif­ic Group, Health­Cap and Advanced Tech­nol­o­gy Ventures.